NEWS
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
Cocrystal Pharma (Nasdaq: COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of its Phase 1 study for CDI-988, an oral pan-viral norovirus/coronavirus protease inhibitor.
The study, conducted in Australia, evaluated doses ranging from 100 mg to 600 mg in healthy adults. Key findings include:
- No serious adverse events or severe treatment-emergent adverse events
- No clinically significant observations in laboratory assessments, physical exams, or electrocardiograms
- All participants completed the study with no discontinuations
- No serious adverse events or severe treatment-emergent adverse events
- No clinically significant observations in laboratory assessments, physical exams, or electrocardiograms
- All participants completed the study with no discontinuations
CDI-988 is being developed as the first dual, broad-spectrum antiviral for norovirus and coronavirus treatment.
The company plans to begin multiple-ascending dose (MAD) cohorts in Q4 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1075Followers
68Following
7381Visitors
Follow